Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Bladder Cancer

Free Subscription 06.05.2024 1 Am J Clin Pathol 1 Ann Ital Chir 1 Ann Oncol 1 Ann Surg Oncol 5 Anticancer Res 1 Asian J Urol 1 Biomedicines 1 BJU Int 1 BMC Med Imaging 2 BMJ Case Rep 1 Cancer Biother Radiopharm 1 Cancer Immunol Res 2 Cancers (Basel) 1 Cell Death Discov 1 Clin Genitourin Cancer 1 Crit Rev Oncol Hematol 1 Curr Oncol Rep 1 Discov Oncol 1 Eur J Med Res 1 Eur J Ophthalmol 1 Eur Urol Focus 1 Heliyon 1 Int J Mol Sci 1 Int J Nanomedicine 3 Int J Urol 1 iScience 1 J Autoimmun 1 J Cell Mol Med 1 J Clin Anesth 2 J Clin Med 1 J Endourol 1 J Mol Diagn 1 J Urol 2 JAMA Netw Open 1 JCO Precis Oncol 1 Korean J Physiol Pharmacol 1 Med Lett Drugs Ther 1 Medicina (Kaunas) 1 Medicine (Baltimore) 1 Molecules 1 Nanoscale Horiz 1 Nat Rev Drug Discov 1 Pharmacoepidemiol Drug Saf 1 R I Med J (2013) 2 Scand J Urol 1 Transl Oncol 1 Trends Mol Med 4 Urol Oncol 1 Urology 1 Virchows Arch 1 World J Clin Oncol 2 World J Urol 1 Zhonghua Bing Li Xue Za Zhi

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Clin Pathol

1. SAUNDERS KE, Gerken N, Khani F, Williamson SR, et al
   Current gross examination and reporting patterns of post-neoadjuvant chemotherapy cystectomy specimens: Is it time for a standardized approach?
   Am J Clin Pathol. 2024;161:483-489.
   PubMed         Abstract available
   
   

   
   Ann Ital Chir

2. LI J
   Correlation between Ki-67 or Profilin-1 Expression Levels, Clinicopathological Characteristics and Postoperative Prognosis in Patients with Bladder Cancer.
   Ann Ital Chir. 2024;95:246-252.
   PubMed         Abstract available
   
   

   
   Ann Oncol

3. BERTUCCI F, de Nonneville A, Finetti P, Cohendet A, et al
   The co-expression of antigen targets as a rationale for ADC combination in urothelial cancer.
   Ann Oncol. 2024;35:477-478.
   PubMed        
   
   

   
   Ann Surg Oncol

4. SLUSARCZYK A, Ismail H, Zapala L, Piecha T, et al
   ASO Visual Abstract: Changes in the Urinary Microbiome following Transurethral Resection of Non-muscle-invasive Bladder Cancer-Insights from a Prospective Observational Study.
   Ann Surg Oncol. 2024 Apr 26. doi: 10.1245/s10434-024-15340.
   PubMed        
   
   

   
   Anticancer Res

5. KOBATAKE K, Ikeda K, Kohada Y, Tasaka R, et al
   Muscle-Invasive Bladder Cancer With Hydronephrosis Exhibits a High Frequency of Mutations in Fibroblast Growth Factor Receptor 3 Gene.
   Anticancer Res. 2024;44:1947-1954.
   PubMed         Abstract available
   
   
6. HUBER F, Wolf I, Storz J, Schultze-Seemann S, et al
   Antibody-dye Conjugates Targeting EGFR and HER2 for the Photoimmunotherapy of Bladder Cancer.
   Anticancer Res. 2024;44:1837-1844.
   PubMed         Abstract available
   
   
7. FUKUOKAYA W, Akazawa K, Kimura T
   Association Between Serum Magnesium Levels and Outcomes of Atezolizumab in Patients With Metastatic Urothelial Carcinoma.
   Anticancer Res. 2024;44:2117-2123.
   PubMed         Abstract available
   
   
8. FUCHIZAWA H, Ando K, Motoi N, Iizuka T, et al
   STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-gamma-induced Apoptosis in Urothelial Cancer.
   Anticancer Res. 2024;44:1925-1930.
   PubMed         Abstract available
   
   
9. CHEN CH, Chen YC, Chang YC, Hung CH, et al
   Taurine Rescues Cancer-induced Atrophy in Human Skeletal Muscle Cells via Ameliorating the Inflammatory Tumor Microenvironment.
   Anticancer Res. 2024;44:1963-1971.
   PubMed         Abstract available
   
   

   
   Asian J Urol

10. GARCIA-PERDOMO HA, Davila-Raigoza AM, Korkes F
    Metabolomics for the diagnosis of bladder cancer: A systematic review.
    Asian J Urol. 2024;11:221-241.
    PubMed         Abstract available
    
    

    
    Biomedicines

11. KAPRINIOTIS K, Tzelves L, Lazarou L, Mitsogianni M, et al
    Circulating Tumour DNA and Its Prognostic Role in Management of Muscle Invasive Bladder Cancer: A Narrative Review of the Literature.
    Biomedicines. 2024;12:921.
    PubMed         Abstract available
    
    

    
    BJU Int

12. BREE KK, Janes JL, Hensley PJ, Srinivasan A, et al
    Racial disparities in stage at bladder cancer diagnosis in the US Veterans Affairs healthcare system.
    BJU Int. 2024 Apr 29. doi: 10.1111/bju.16380.
    PubMed         Abstract available
    
    

    
    BMC Med Imaging

13. ZHANG R, Jia S, Zhai L, Wu F, et al
    Predicting preoperative muscle invasion status for bladder cancer using computed tomography-based radiomics nomogram.
    BMC Med Imaging. 2024;24:98.
    PubMed         Abstract available
    
    

    
    BMJ Case Rep

14. YOUSSEF M, Sewell J, Grills R
    Unrecognised paraganglioma of the urinary bladder precipitating hypertensive crisis.
    BMJ Case Rep. 2024;17:e259283.
    PubMed         Abstract available
    
    
15. REWARI H, Wadhwa P, Talwar H, Taneja D, et al
    Anastomosing haemangioma of adrenal gland: an unusual vascular tumour.
    BMJ Case Rep. 2024;17:e259092.
    PubMed         Abstract available
    
    

    
    Cancer Biother Radiopharm

16. AI J, Zhang S, Qian Y, Kang L, et al
    Radiotherapy and Anrotinib in Malignant Glomus Tumor of the Bladder: A Case Report and Literature Review.
    Cancer Biother Radiopharm. 2024;39:318-321.
    PubMed         Abstract available
    
    

    
    Cancer Immunol Res

17. PRAHARAJ M, Shen F, Lee AJ, Zhao L, et al
    Metabolic reprogramming of tumor-associated macrophages using glutamine antagonist JHU083 drives tumor immunity in myeloid-rich prostate and bladder cancer tumors.
    Cancer Immunol Res. 2024 May 3. doi: 10.1158/2326-6066.CIR-23-1105.
    PubMed         Abstract available
    
    

    
    Cancers (Basel)

18. STROMME O, Heck KA, Brede G, Lindholm HT, et al
    tRNA-Derived Fragments as Biomarkers in Bladder Cancer.
    Cancers (Basel). 2024;16:1588.
    PubMed         Abstract available
    
    
19. TOTONJI S, Ramos-Triguero A, Willmann D, Sum M, et al
    Lysine Methyltransferase 9 (KMT9) Is an Actionable Target in Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2024;16:1532.
    PubMed         Abstract available
    
    

    
    Cell Death Discov

20. SCIMECA M, Bischof J, Bonfiglio R, Nale E, et al
    Molecular profiling of a bladder cancer with very high tumour mutational burden.
    Cell Death Discov. 2024;10:202.
    PubMed         Abstract available
    
    

    
    Clin Genitourin Cancer

21. SUARTZ CV, Martinez LM, Cordeiro MD, Botelho LAA, et al
    Honing the Hunt: A Comprehensive Review of Cell-free Tumor DNA to Predict Neoadjuvant Therapy Efficacy in Bladder Cancer.
    Clin Genitourin Cancer. 2024;22:102087.
    PubMed         Abstract available
    
    

    
    Crit Rev Oncol Hematol

22. FUJIWARA Y, Karol AB, Joshi H, Reford E, et al
    C-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysis.
    Crit Rev Oncol Hematol. 2024;197:104352.
    PubMed         Abstract available
    
    

    
    Curr Oncol Rep

23. LIU MA, Li JW, Runcie K
    Management of Oligometastatic and Locally Recurrent Urothelial Carcinoma.
    Curr Oncol Rep. 2024;26:496-503.
    PubMed         Abstract available
    
    

    
    Discov Oncol

24. ZHAO F, Jia Z, Xie H
    Identification of a pyroptosis-immune-related lncRNA signature for prognostic and immune landscape prediction in bladder cancer patients.
    Discov Oncol. 2024;15:140.
    PubMed         Abstract available
    
    

    
    Eur J Med Res

25. ZHANG W, Chen XS, Wei Y, Wang XM, et al
    Overexpressed KCNK1 regulates potassium channels affecting molecular mechanisms and biological pathways in bladder cancer.
    Eur J Med Res. 2024;29:257.
    PubMed         Abstract available
    
    

    
    Eur J Ophthalmol

26. PARIS A, Bodaghi B, Touhami S
    Pan fibroblast growth factor receptor inhibitor associated retinopathy.
    Eur J Ophthalmol. 2023 Dec 12:11206721231220334. doi: 10.1177/11206721231220334.
    PubMed         Abstract available
    
    

    
    Eur Urol Focus

27. LIN YH, Tsai HY, Tsao SH
    Re: Steven Monda, Manolis Pratsinis, Hansen Lui, et al. Secondary Bladder Cancer After Prostate Cancer Treatment: An Age-matched Comparison Between Radiation and Surgery. Eur Urol Focus. In press. http://doi.org/10.1016/j.euf.2023.09.002.
    Eur Urol Focus. 2024 Apr 25:S2405-4569(24)00061.
    PubMed        
    
    

    
    Heliyon

28. LIU S, Wang Y, Duan L, Cui D, et al
    Whole transcriptome sequencing identifies a competitive endogenous RNA network that regulates the immunity of bladder cancer.
    Heliyon. 2024;10:e29344.
    PubMed         Abstract available
    
    

    
    Int J Mol Sci

29. MONYOK A, Mansour B, Vadnay I, Makra N, et al
    Change in Tissue Microbiome and Related Human Beta Defensin Levels Induced by Antibiotic Use in Bladder Carcinoma.
    Int J Mol Sci. 2024;25:4562.
    PubMed         Abstract available
    
    

    
    Int J Nanomedicine

30. YIN C, Liufu C, Zhu T, Ye S, et al
    Bladder Cancer in Exosomal Perspective: Unraveling New Regulatory Mechanisms.
    Int J Nanomedicine. 2024;19:3677-3695.
    PubMed         Abstract available
    
    

    
    Int J Urol

31. KAWAI T, Matsuyama H, Kobayashi K, Ikeda A, et al
    Photodynamic diagnosis-assisted transurethral resection of bladder tumor for high-risk non-muscle invasive bladder cancer improves intravesical recurrence-free survival (BRIGHT study).
    Int J Urol. 2024 May 2. doi: 10.1111/iju.15483.
    PubMed         Abstract available
    
    
32. MIYAKE M, Nishimura N, Nakahama T, Nishimoto K, et al
    Differences in oncological benefits from second transurethral resection between white-light initial surgery and photodynamic diagnosis-guided initial surgery for primary high-risk non-muscle invasive bladder cancer.
    Int J Urol. 2024 Apr 30. doi: 10.1111/iju.15474.
    PubMed         Abstract available
    
    
33. SHIOTA M, Nagakawa S, Tsukahara S, Matsumoto T, et al
    Independent validation of genetic risk model to progression after intravesical bacillus Calmette-Guerin therapy for non-muscle invasive bladder cancer.
    Int J Urol. 2024 Apr 30. doi: 10.1111/iju.15484.
    PubMed        
    
    

    
    iScience

34. LI T, You Q, Zhang S, Li R, et al
    Performance of (18)F-FDG PET/MRI and its parameters in staging and neoadjuvant therapy response evaluation in bladder cancer.
    iScience. 2024;27:109657.
    PubMed         Abstract available
    
    

    
    J Autoimmun

35. LI J, Cheng C, Zhang J
    Autoimmune diseases and the risk of bladder cancer: A Mendelian randomization analysis.
    J Autoimmun. 2024;146:103231.
    PubMed         Abstract available
    
    

    
    J Cell Mol Med

36. MENECEUR S, De Vos CE, Petzsch P, Kohrer K, et al
    New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma.
    J Cell Mol Med. 2024;28:e18342.
    PubMed         Abstract available
    
    

    
    J Clin Anesth

37. PARK JY, Yu J, Kim CS, Kim YK, et al
    Reply for Comment on: Vitamin C and catheter-related bladder discomfort after transurethral resection of bladder tumor.
    J Clin Anesth. 2024;95:111445.
    PubMed        
    
    

    
    J Clin Med

38. SANGUEDOLCE F, Falagario UG, Zanelli M, Palicelli A, et al
    Integrating the PD-L1 Prognostic Biomarker in Non-Muscle Invasive Bladder Cancer in Clinical Practice-A Comprehensive Review on State-of-the-Art Advances and Critical Issues.
    J Clin Med. 2024;13:2182.
    PubMed         Abstract available
    
    
39. SARRIO-SANZ P, Martinez-Cayuelas L, Beltran-Perez A, Munoz-Montoya M, et al
    A Novel Decision Tree Model for Predicting the Cancer-Specific Survival of Patients with Bladder Cancer Treated with Radical Cystectomy.
    J Clin Med. 2024;13:2177.
    PubMed         Abstract available
    
    

    
    J Endourol

40. FANG AM, Hayek O, Kaylor JM, Peyton CC, et al
    Postoperative Outcomes and Analgesic Requirements of Single-Port vs Multiport Robotic-Assisted Radical Cystectomy.
    J Endourol. 2024;38:438-443.
    PubMed         Abstract available
    
    

    
    J Mol Diagn

41. BANG BR, Zhong J, Oh TJ, Lee JY, et al
    A Streamlined PENK Methylation Test in Urine DNA, EarlyTect BCD, Effectively Detects Bladder Cancer in Patients with Hematuria.
    J Mol Diagn. 2024 Apr 25:S1525-1578(24)00084.
    PubMed         Abstract available
    
    

    
    J Urol

42. KARABURUN MC, Kuz ED, Akpinar C, Obaid K, et al
    Grade Heterogeneity in High-Grade Urothelial Carcinomas: Does It Have an Impact on the Survival of Patients With Intermediate/High-Risk Nonmuscle-Invasive Bladder Cancer Who Received Adequate Adjuvant Bacillus Calmette-Guerin Therapy?
    J Urol. 2024 May 1:101097JU0000000000003990. doi: 10.1097/JU.0000000000003990.
    PubMed         Abstract available
    
    

    
    JAMA Netw Open

43. KOSHKIN VS
    Therapy Attrition and Lessons for Future Approaches to Treatment of Advanced Urothelial Cancer.
    JAMA Netw Open. 2024;7:e249426.
    PubMed        
    
    
44. MATHEW THOMAS V, Jo Y, Tripathi N, Roy S, et al
    Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the US.
    JAMA Netw Open. 2024;7:e249417.
    PubMed         Abstract available
    
    

    
    JCO Precis Oncol

45. LENIS AT, Whiting K, Ravichandran V, Tallman JE, et al
    Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer.
    JCO Precis Oncol. 2024;8:e2300274.
    PubMed         Abstract available
    
    

    
    Korean J Physiol Pharmacol

46. LIN P, Yang X, Wang L, Zou X, et al
    Novel artesunate-metformin conjugate inhibits bladder cancer cell growth associated with Clusterin/SREBP1/FASN signaling pathway.
    Korean J Physiol Pharmacol. 2024;28:219-227.
    PubMed         Abstract available
    
    

    
    Med Lett Drugs Ther

47. 
    Erdafitinib (Balversa) for urothelial carcinoma.
    Med Lett Drugs Ther. 2024;66:e83-e84.
    PubMed        
    
    

    
    Medicina (Kaunas)

48. PEZZICOLI G, Ciciriello F, Musci V, Minei S, et al
    Genomic Profiling and Molecular Characterisation of Metastatic Urothelial Carcinoma.
    Medicina (Kaunas). 2024;60:585.
    PubMed         Abstract available
    
    

    
    Medicine (Baltimore)

49. YE Z, Liu C, Wu S, Jin X, et al
    Identification of cuproptosis-related long non-coding RNA and construction of a novel prognostic signature for bladder cancer: An observational study.
    Medicine (Baltimore). 2024;103:e38005.
    PubMed         Abstract available
    
    

    
    Molecules

50. ETURI A, Bhasin A, Zarrabi KK, Tester WJ, et al
    Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma.
    Molecules. 2024;29:1896.
    PubMed         Abstract available
    
    

    
    Nanoscale Horiz

51. BHARTI AM, Rakesh Kumar RK, Chuang CH, Shaikh MO, et al
    Universal nanocomposite coating with antifouling and redox capabilities for electrochemical affinity biosensing in complex biological fluids.
    Nanoscale Horiz. 2024;9:843-852.
    PubMed         Abstract available
    
    

    
    Nat Rev Drug Discov

52. MULLARD A
    First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer.
    Nat Rev Drug Discov. 2024 Apr 26. doi: 10.1038/d41573-024-00073.
    PubMed        
    
    

    
    Pharmacoepidemiol Drug Saf

53. WANG LS, Hubbard RA, Mamtani R
    Comparing survival in trial- versus routine-care advanced urothelial cancer patients on immune checkpoint blockade.
    Pharmacoepidemiol Drug Saf. 2024;33:e5798.
    PubMed         Abstract available
    
    

    
    R I Med J (2013)

54. REDDY AC, Gu JZ, Koo BH, Fruh V, et al
    Urothelial Carcinoma: Epidemiology and Imaging-Based Review.
    R I Med J (2013). 2024;107:26-32.
    PubMed         Abstract available
    
    

    
    Scand J Urol

55. ABUHASANEIN S, Edenbrandt L, Enqvist O, Jahnson S, et al
    A novel model of artificial intelligence based automated image analysis of CT urography to identify bladder cancer in patients investigated for macroscopic hematuria.
    Scand J Urol. 2024;59:90-97.
    PubMed         Abstract available
    
    
56. LIEDBERG F, Hagberg O, Aljabery F, Andren O, et al
    Cystectomy for bladder cancer in Sweden - short-term outcomes after centralization.
    Scand J Urol. 2024;59:84-89.
    PubMed         Abstract available
    
    

    
    Transl Oncol

57. LU C, Gao H, Li H, Luo N, et al
    A novel LINC02321 promotes cell proliferation and decreases cisplatin sensitivity in bladder cancer by regulating RUVBL2.
    Transl Oncol. 2024;45:101962.
    PubMed         Abstract available
    
    

    
    Trends Mol Med

58. BEN-DAVID R, Galsky MD, Sfakianos JP
    Novel bladder-sparing approaches in patients with muscle-invasive bladder cancer.
    Trends Mol Med. 2024 Apr 30:S1471-4914(24)00092.
    PubMed         Abstract available
    
    

    
    Urol Oncol

59. XIA L, Dadabhoy A, Wood EL, Mehta SV, et al
    Pathologic and survival outcomes following radical cystectomy for "progressive" and "de novo" muscle-invasive bladder cancer: A meta-analysis stratified by neoadjuvant chemotherapy status.
    Urol Oncol. 2024 May 1:S1078-1439(24)00438-1. doi: 10.1016/j.urolonc.2024.
    PubMed         Abstract available
    
    
60. INGRAM JW, Chung R, Laplaca C, McKiernan JM, et al
    Incidence and management of prostatic urethra recurrence in a cohort of 21 patients who received BCG induction for non-muscle invasive bladder cancer.
    Urol Oncol. 2024 Apr 29:S1078-1439(24)00436.
    PubMed         Abstract available
    
    
61. MAMTANI R, Tsingas K, Parikh RB, Elsouda D, et al
    Real-world use, dose intensity, and adherence to enfortumab vedotin in locally advanced or metastatic urothelial cancer.
    Urol Oncol. 2024;42:177.
    PubMed         Abstract available
    
    
62. MELGAREJO SEGURA MT, Yanez Castillo Y, Lozano Lorca M, Morales Martinez A, et al
    Efficacy of conduction hyperthermia in the treatment of non-muscle invasive bladder cancer: A systematic review.
    Urol Oncol. 2024 Apr 25:S1078-1439(24)00399.
    PubMed         Abstract available
    
    

    
    Urology

63. EULE CJ, Warren A, Kuna EM, Callihan EB, et al
    Neoadjuvant cisplatin-based chemotherapy in nonmetastatic muscle-invasive bladder cancer: A systematic review and pooled meta-analysis to determine the preferred regimen.
    Urology. 2024 Apr 27:S0090-4295(24)00306-6. doi: 10.1016/j.urology.2024.
    PubMed         Abstract available
    
    

    
    Virchows Arch

64. RUSCHOFF J, Kumar G, Badve S, Jasani B, et al
    Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology Assessments.
    Virchows Arch. 2024;484:597-608.
    PubMed         Abstract available
    
    

    
    World J Clin Oncol

65. GADE VKV, Yadav BS
    Understanding the role of transmembrane 9 superfamily member 1 in bladder cancer pathogenesis.
    World J Clin Oncol. 2024;15:468-471.
    PubMed         Abstract available
    
    

    
    World J Urol

66. PELLEGRINO F, Leni R, Basile G, Rosiello G, et al
    Peri- and post-operative outcomes of robot-assisted radical cystectomy after the implementation of the EAU guidelines recommendations for collecting and reporting complications at a high-volume referral center.
    World J Urol. 2024;42:270.
    PubMed         Abstract available
    
    
67. LIN FX, Wang L, Xu ZP
    A balanced perspective on bladder preservation and systemic treatment in muscle-invasive bladder cancer.
    World J Urol. 2024;42:288.
    PubMed        
    
    

    
    Zhonghua Bing Li Xue Za Zhi

68. CHEN L, Liu LT, Sun MJ, He SR, et al
    [Practical application of the Paris system for reporting urinary cytology].
    Zhonghua Bing Li Xue Za Zhi. 2024;53:470-476.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.